Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co. Looks To Artiva’s Off-The-Shelf Cell Therapy Technologies

Executive Summary

Deal Snapshot: Pharma places $30m upfront wager on biotech’s allogeneic natural killer cell and chimeric antigen receptor technologies, with hopes for solid tumor cell therapies.

You may also be interested in...



The Race Is On. When Will Korea Have Its Own Approved Gene Therapy?

Scrip takes a look at the landscape of the South Korean gene and cell therapy sector, which is under the spotlight with the implementation of a new cutting-edge biologics law.

Korea 2021 Roundup: License Deals, Overseas Sales Key Factors In Earnings

A Scrip roundup of 2021 earnings for major Korean pharma firms shows top performers included Hanmi Pharma, GC Pharma and SK Group affiliates, which were boosted by new license deals, strong overseas sales and high-margin vaccines and other products.

Korean Biopharmas Set For Another Record Year Of Licensing Deals

Scrip takes a look at South Korea’s out-licensing deal trends for 2021, finding that more big transactions are likely as the year moves towards its close despite a wider global slowing in activity, helped by rising innovative R&D.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel